Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Prime Medicine Inc (NASDAQ: PRME) closed at $3.29 in the last session, up 9.87% from day before closing price of $2.99. In other words, the price has increased by $9.87 from its previous closing price. On the day, 1.41 million shares were traded.
Ratios:
We take a closer look at PRME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.50 and its Current Ratio is at 6.50. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on December 10, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On May 20, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
Citigroup Upgraded its Neutral to Buy on May 16, 2024, while the target price for the stock was maintained at $10.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 538.58 while its Price-to-Book (P/B) ratio in mrq is 2.27.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $9.77, while it has fallen to a 52-week low of $2.25. The 50-Day Moving Average of the stock is 13.46%, while the 200-Day Moving Average is calculated to be -24.64%.
Shares Statistics:
A total of 131.16M shares are outstanding, with a floating share count of 51.87M. Insiders hold about 60.45% of the company’s shares, while institutions hold 31.03% stake in the company.
